Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von Vimeo.Mehr erfahren
Video laden
Vimeo immer entsperren
Hochrisiko-MDS
Immuntherapie
Anti-CD47-Antikörper Magrolimab
The First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine Is Well-Tolerated And Effective In MDS Patients: Phase 1b Results. Sallman David et al., EHA25 virtual, Abstr. #S187
Anti-Tim-3-Antikörper MBG453
Anti-TIM-3 Antibody MBG453 In Combination With Hypomethylating Agents (HMAs) In Patients (Pts) With High-Risk Myelodysplastic Syndrome (HR-MDS) And Acute Myeloid Leukemia (AML): A Phase 1 Study. Uma Borate et al., EHA25 virtual, #Abstr S185
Zielgerichtete Therapie
APR-246 – Target ist mutiertes p53
APR-246 Combined With Azacitidine In Tp53 Mutated Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukemia. A Phase 2 Study By The Groupe Francophone Des Myélodysplasies (GFM). Thomas Cluzeau et al., EHA25 virtual, Abstr. # S181
A Phase 1b Study Evaluating The Safety And Efficacy Of Venetoclax In Combination With Azacitidine For The Treatment Of Relapsed/Refractory Myelodysplastic Syndrome. Amer M. Zeidan et al., EHA25 virtual, Abstr. #S188
Proteasomeninhibitor Pevonedistat
Phase 2 Study Of Pevonedistat + Azacitidine Versus Azacitidine In Patients With Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia Or Low-Blast Acute Myelogenous Leukemia. Lionel Ades et al., EHA25 virtual, Abstr. #S182
Niedrigrisiko-MDS
Luspatercept bei hoher Transfusionslast – Auswertung der MEDALIST-Studie (Zeidan et al.)
Clinical Benefit Of Luspatercept In Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) And High Transfusion Burden (HTB) In The Phase 3 MEDALIST Study. Amer M. Zeidan et al., EHA25 virtual, Abstr. # EP798
Dosisabhängiges Ansprechen auf Luspatercept – Auswertung der MEDALIST-Studie (Platzbecker et al.)
Assessment Of Dose-Dependent Response To Luspatercept In Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) With Ring Sideroblasts In The Phase 3 MEDALIST Trial. Uwe Platzbecker et al., EHA25 virtual, Abstr. #EP812
Telomerase-Inhibitor Imetelstat
https://library.ehaweb.org/eha/2020/eha25th/295003/uwe.platzbecker.treatment.with.imetelstat.provides.durable.transfusion.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dtelomerase+inhibitor
